Mary Fisher - 21 Jan 2025 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Reporting relationship: Director
Issuer ticker: DRMA
Reported as of: 21 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jan 2025, 17:04:18 UTC
Prior SEC filing: 14 Jan 2025
Next SEC filing: 06 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Gerald T. Proehl, Attorney-in-Fact

Key filing fact

Mary Fisher filed Form 4 for Dermata Therapeutics, Inc. (DRMA) on 23 Jan 2025.

Key facts

This page summarizes Mary Fisher's Form 4 filing for Dermata Therapeutics, Inc. (DRMA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Jan 2025, 17:04.

Change

Previous filing in this sequence was filed on 14 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DRMA transaction

Common Stock

Award

Transaction value
Shares: +196,851
Change %: +207212%
Price
Shares after: 196,946
Date: 21 Jan 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DRMA transaction Derivative

Warrant (Right to Buy)

Award

Transaction value
Shares: +196,851
Change %
Price
Shares after: 196,851
Date: 21 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 196,851
Exercise price: $1.27
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Footnote F2

The purchase price per share of Common Stock and accompanying Warrant was $1.27.

Footnote F3

The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.